Source: CureToday articles
Itovebi plus Ibrance and Faslodex improved overall survival in patients with PIK3CA-mutant, HR+, HER2–, endocrine-resistant breast cancer versus placebo.
Recent Content
- Breaking Down Treatment Variables in AYA Patients With Cancer
- ASCO25 Preview: Key Research Accelerating Cancer Care
- Zepzelca Plus Tecentriq Boosts Survival in First-Line ES-SCLC Care
- Itovebi Triplet Combo Boosts Survival in HR+, HER2– Breast Cancer
- FDA Approves Ranibizumab Injection for Treatment of Diabetic Retinopathy
- FDA Approves Mepolizumab for Treatment of Patients With COPD and an Eosinophilic Phenotype
- Distinct NK Cell Subset Predicts Ibrutinib Response and Immune Pathway Activation in CLL
- Community Pharmacy Applauds House Passage of PBM Reform Provisions in Budget Bill
- FDA Grants Interchangeability Designation to Yuflyma, Biosimilar for Humira Across All Approved Doses
- The Mentorship Model: Cultivating Resilience and Leadership in Palliative Care Pharmacy